News from NORD

Join the National Organization for Rare Disorders and the University of Massachusetts for Two Upcoming CME-Accredited Events


 

Do you currently treat patients with rare diseases? Do you suspect that you might have a patient with an undiagnosed rare disease? The National Organization for Rare Disorders (NORD) and the University of Massachusetts Medical School have designed two events for you and your colleagues to learn more about rare diseases and the available diagnostic tools.

An interactive half-day symposium on diagnostic hurdles, tools, and resources is planned for Sunday, October 16, 2017, at the Marriott Wardman Park Hotel in Washington DC. This event, “Finding a Zebra Among Many Horses,” will focus on challenges and resources related to rare disease diagnosis.

On the following two days, Oct. 16 and 17, NORD’s Rare Diseases and Orphan Products Breakthrough Summit will take place at the same location and is also CME-accredited. Topics to be covered will include:

  • Assuring Patient Access: Future Outlook for Patient Assistance Programs
  • The Challenge of Health Care Costs and Treatment Prices
  • An Evergreen and Sustainable Approach to Orphan Drugs
  • Next-Generation Treatments and Advancing Clinical Trials

The NORD Breakthrough Summit attracts approximately 600 participants from rare disease stakeholder groups, including clinicians, researchers, patient advocates, and government partners from the NIH and FDA.

Online registration is available now for either or both events.

Recommended Reading

Neuroendocrine Tumor Research Foundation Issues Request for Proposals
MDedge Dermatology
Spinal CSF Leak Foundation and Cedars-Sinai Plan Intracranial Hypotension Symposium
MDedge Dermatology
Vestibular Disorders Association Celebrates Balance Awareness Week
MDedge Dermatology
New genetic causes of ichthyoses likely to emerge
MDedge Dermatology
Amyopathic Dermatomyositis With Plantar Keratoderma Responding to Methotrexate Therapy
MDedge Dermatology
Developing vaccines against enterovirus-A71 called a priority
MDedge Dermatology
FDA grants breakthrough status to epidermolysis bullosa gene therapy
MDedge Dermatology
Presumed Serum Sickness Following Thymoglobulin Treatment of Acute Cellular Rejection of a Cardiac Allograft
MDedge Dermatology
Targeted therapy may be possible for pityriasis rubra pilaris
MDedge Dermatology
Immunologic testing is key to diagnosing autoimmune blistering diseases
MDedge Dermatology